… Author links open overlay panel Angela Di Giannatale a 1 , Nathalie Dias-Gastellier a 1 ,
Annick Devos b 1 , Kieran Mc Hugh c 1 , Ariane Boubaker d 1 , Frederic Courbon e 1 , Arnaud …

In the European Union, the pediatric medicines regulation in 2007 modified significantly the
access to new agents in pediatric oncology. Early oncology trials are still thought to be …

Introduction COVID-19 restrictive containment was responsible for major psychological distress
and alteration of quality of life (QoL) in the general population. Their impact in a group of …

BACKGROUND AND PURPOSE: By studying the evolution of brain volume across the life
span in male and female patients, we aimed to understand how sex, brain volume, and the …

Background: For developing future clinical trials in Cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy (CADASIL), it seems crucial to study the …

In clinical studies, SIENA [1] is the reference tool to estimate brain atrophy, a key MRI-based
feature strongly related to neurological and physical disabilities in small vessel disease as …

Objective: To obtain simple models predicting disease evolution at 3 years for a given
patient with cerebral autosomal dominant arteriopathy with subcortical infarcts and …

… We thank very much Mr Abbas Taleb for collecting most of information along the cohort study
and Mrs Nathalie Dias-Gastellier and Fanny Fernandes, the research managers in charge …

PURPOSE The aim of the Innovative Therapies for Children with Cancer (ITCC) consortium
is to improve access to novel therapies for children and adolescents with cancer. The …

The ‘Individualized Therapy for Relapsed Malignancies in Childhood’ (INFORM) precision
medicine study is a nationwide German program for children with high-risk relapsed/refractory …